Meibum Expression
ProcedureMeibum expression as per protocol. No investigational drug is administered in this study.
NCT Number: NCT01979887
This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
London, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-Participants characterized as with or without Meibomian Gland Dysfunction.
Exclusion criteria
Meibum expression as per protocol. No investigational drug is administered in this study.
Time frame: Day 22
Allergan
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03226769
Dry Eye Syndromes, Eye Diseases
Andover, Massachusetts, United States
View Trial Details